Medtech Execs On The Move, June-July 2014
Executive Summary
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Eric Compton Takes Reins At Z-Medica
Eric Compton, a rising industry executive is set to take the helm at the hemostatic device-maker Z-Medica. He follows in the footsteps of President and CEO Stephen Fanning.
‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals
Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.
Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims
US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.